IBDEI39Y ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,52262,1,3,0)
 ;;=3^DM Type 1 w/ Unspec Compl
 ;;^UTILITY(U,$J,358.3,52262,1,4,0)
 ;;=4^E10.8
 ;;^UTILITY(U,$J,358.3,52262,2)
 ;;=^5002625
 ;;^UTILITY(U,$J,358.3,52263,0)
 ;;=E10.9^^193^2526^34
 ;;^UTILITY(U,$J,358.3,52263,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52263,1,3,0)
 ;;=3^DM Type 1 w/o Compl
 ;;^UTILITY(U,$J,358.3,52263,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,52263,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,52264,0)
 ;;=E10.620^^193^2526^5
 ;;^UTILITY(U,$J,358.3,52264,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52264,1,3,0)
 ;;=3^DM Type 1 w/ Diab Dermatitis
 ;;^UTILITY(U,$J,358.3,52264,1,4,0)
 ;;=4^E10.620
 ;;^UTILITY(U,$J,358.3,52264,2)
 ;;=^5002615
 ;;^UTILITY(U,$J,358.3,52265,0)
 ;;=E10.36^^193^2526^4
 ;;^UTILITY(U,$J,358.3,52265,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52265,1,3,0)
 ;;=3^DM Type 1 w/ Diab Cataract
 ;;^UTILITY(U,$J,358.3,52265,1,4,0)
 ;;=4^E10.36
 ;;^UTILITY(U,$J,358.3,52265,2)
 ;;=^5002602
 ;;^UTILITY(U,$J,358.3,52266,0)
 ;;=E10.621^^193^2526^6
 ;;^UTILITY(U,$J,358.3,52266,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52266,1,3,0)
 ;;=3^DM Type 1 w/ Diab Foot Ulcer
 ;;^UTILITY(U,$J,358.3,52266,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,52266,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,52267,0)
 ;;=E10.622^^193^2526^28
 ;;^UTILITY(U,$J,358.3,52267,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52267,1,3,0)
 ;;=3^DM Type 1 w/ Oth Skin Ulcer
 ;;^UTILITY(U,$J,358.3,52267,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,52267,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,52268,0)
 ;;=E10.51^^193^2526^32
 ;;^UTILITY(U,$J,358.3,52268,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52268,1,3,0)
 ;;=3^DM Type 1 w/ Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,52268,1,4,0)
 ;;=4^E10.51
 ;;^UTILITY(U,$J,358.3,52268,2)
 ;;=^5002610
 ;;^UTILITY(U,$J,358.3,52269,0)
 ;;=E10.52^^193^2526^31
 ;;^UTILITY(U,$J,358.3,52269,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52269,1,3,0)
 ;;=3^DM Type 1 w/ Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,52269,1,4,0)
 ;;=4^E10.52
 ;;^UTILITY(U,$J,358.3,52269,2)
 ;;=^5002611
 ;;^UTILITY(U,$J,358.3,52270,0)
 ;;=E11.00^^193^2527^19
 ;;^UTILITY(U,$J,358.3,52270,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52270,1,3,0)
 ;;=3^DM Type 2 w/ Hyperosmolarity w/o NKHHC
 ;;^UTILITY(U,$J,358.3,52270,1,4,0)
 ;;=4^E11.00
 ;;^UTILITY(U,$J,358.3,52270,2)
 ;;=^5002627
 ;;^UTILITY(U,$J,358.3,52271,0)
 ;;=E11.01^^193^2527^18
 ;;^UTILITY(U,$J,358.3,52271,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52271,1,3,0)
 ;;=3^DM Type 2 w/ Hyperosmolarity w/ Coma
 ;;^UTILITY(U,$J,358.3,52271,1,4,0)
 ;;=4^E11.01
 ;;^UTILITY(U,$J,358.3,52271,2)
 ;;=^5002628
 ;;^UTILITY(U,$J,358.3,52272,0)
 ;;=E11.21^^193^2527^7
 ;;^UTILITY(U,$J,358.3,52272,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52272,1,3,0)
 ;;=3^DM Type 2 w/ Diab Nephropathy
 ;;^UTILITY(U,$J,358.3,52272,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,52272,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,52273,0)
 ;;=E11.22^^193^2527^3
 ;;^UTILITY(U,$J,358.3,52273,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52273,1,3,0)
 ;;=3^DM Type 2 w/ Diab CKD
 ;;^UTILITY(U,$J,358.3,52273,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,52273,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,52274,0)
 ;;=E11.39^^193^2527^28
 ;;^UTILITY(U,$J,358.3,52274,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52274,1,3,0)
 ;;=3^DM Type 2 w/ Oth Diab Ophth Compl
